OR WAIT null SECS
Portfolio features 13 brands spanning six therapeutic areas, mainly revolving around pain management.
Grünenthal GmbH and Kyowa Kirin Co., Ltd. have agreed to enter into a joint venture collaboration for Kyowa Kirin International's established medicines portfolio.
The portfolio comprises 13 brands across six therapeutic areas primarily focused on pain management, including Abstral and PecFent for breakthrough cancer pain, Moventig for opioid-induced constipation, and Adcal-D3 for osteoporosis. All products will continue to be marketed through affiliates in seven major European countries and through a network of partners in various additional territories worldwide; the new enterprise will be branded as Grünenthal Meds.
"The established medicines portfolio has a proud history of delivering life-changing value for patients. Today's announcement now means even more patients, for many years to come, will continue to benefit from the portfolio. We are enormously grateful and proud of our colleagues who have worked tirelessly to make this joint venture collaboration a reality," comments Jeremy Morgan, president, Kyowa Kirin International.
Grünenthal owns a 51% majority share in the joint venture collaboration, while Kyowa Kirin owns a 49% share. Grünenthal plans to fully acquire the remaining 49% share by exercising an option at the beginning of 2026.